SCHEMBL23199846

SCHEMBL23199846

Cc1cc(C(=O)O)nc2c1CCN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.47
▸ TNKS2 Q9H2K2 1/20 0.47
▸ PARP2 Q9UGN5 1/20 0.47
▸ ADORA1 P30542 2/20 0.46
▸ ESR2 Q92731 1/20 0.44
▸ NR1H2 P55055 1/20 0.44
▸ FABP4 P15090 1/20 0.42
▸ FABP5 Q01469 1/20 0.42
▸ F12 P00748 3/20 0.42
▸ MAPT P10636 3/20 0.42
▸ MTOR P42345 1/20 0.41
▸ RAF1 P04049 1/20 0.40
▸ BRAF P15056 1/20 0.40
▸ C5AR1 P21730 1/20 0.39
▸ P2RX3 P56373 1/20 0.39
▸ SPR P35270 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MKNK1 Q9BUB5 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23199026 0.89 C5AR1 (0.43) PARP1TNKS2PARP2ADORA1ESR2
SCHEMBL23198474 0.88 PARP1 (0.46) PARP1TNKS2PARP2ADORA1ESR2
SCHEMBL23202660 0.87 ADORA1 (0.48) PARP1TNKS2PARP2ADORA1ESR2
SCHEMBL23198443 0.86 ADORA1 (0.52) PARP1TNKS2PARP2ADORA1ESR2
SCHEMBL22204312 0.80 PARP1 (0.41) PARP1TNKS2PARP2ADORA1ESR2
SCHEMBL19925934 0.78 PTGER4 (0.43) PARP1TNKS2PARP2ADORA1ESR2
SCHEMBL30474327 0.78 ESR2 (0.55) PARP1TNKS2PARP2ADORA1ESR2
SCHEMBL23200233 0.78 PARP1 (0.38) PARP1TNKS2PARP2ESR2NR1H2
SCHEMBL31576175 0.78 GPR119 (0.47) PARP1TNKS2PARP2ADORA1ESR2
SCHEMBL23198536 0.77 ADORA1 (0.49) PARP1TNKS2PARP2ADORA1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402917-A1 COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF MEDSHINE DISCOVERY INC. (CN) 2022-12-22 — — US disclosed
EP-4043461-A1 COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF Medshine Discovery Inc. (CN) 2022-08-17 — — EP disclosed
WO-2021063404-A1 COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF 南京明德新药研发有限公司 2021-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402917-A1 COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF CD274, PDCD1, PDCD1LG2 PARP1 342/4885TNKS2 1486/4885PARP2 622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback